Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team

You seem to be using a wider screen, would you like to enable a wider viewing experience on this page?

ExpreS2ion Biotechnologies – Presentation of Year-end report 2022

By Michael FriisHead of Equities
ExpreS2ion Biotech Holding

Earlier today, Expres2ion Biotechnologies' CEO Bent Frandsen and CFO Keith Alexander presented the company’s Q4 2022 and full-year financials for 2022.

Besides the financial results, the main focus of the Q&A session was around the COVID-19 vaccine candidate and this morning’s announcement from the partner, Bavarian Nordic, about the timeline delay. 

Disclaimer: HC Andersen Capital receives payment from ExpreS2ion Biotechnologies for a Corporate Visibility/Digital IR subscription agreement. /Michael Friis 16:34, 15 February 2023.

Recent videos

AKTIER MED FRIIS - UGE 50 2025
12.12.2025, 12.00
HCA Morgenbørs 12/12 - Positive futures og fokus på FLSmidth og fedme aktier
12.12.2025, 09.27 Novo Nordisk
A sit-down with CEO Remco Westermann
12.12.2025, 09.09 Verve Group
Aiforia as an Investment | Life Science Night Dec 9, 2025
11.12.2025, 11.00 Aiforia Technologies
HCA Morgenbørs 11/12 - Flade europæiske futures, Oracle skaber usikkerhed om AI
11.12.2025, 09.45 GreenMobility
View all videos
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.